Potential Lung Risks Found in New Cholesterol Medications, Reveals Global Study
Originally Published 2 years ago — by SciTechDaily
A groundbreaking global study analyzing genetic data from 340,000 UK Biobank participants has found that PCSK9 inhibitors, a new class of cholesterol-lowering drugs, could potentially impair lung function. The study also revealed correlations between statins and higher BMI, body fat, and reduced testosterone, while unexpectedly noting an increase in hippocampus brain volume that may lower dementia and depression risks. Further research is needed to understand the long-term effects of these medications and to assess their safety and potential benefits.